Calcium channel blockers versus other classes of drugs for hypertension

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Zhou, Muke ^a   Chen, Ning ^a   Yang, Mi ^a   Guo, Jian ^a   Zhu, Cairong ^b   Yang, Jie ^a   Wang, Yucai ^a   Yang, Xue ^a   He, Li ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT;

BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; HEART IARCTION; HUMAN; HYPERTENSION; MORBIDITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; STROKE;

EID: 70049083438     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003654.pub3     Document Type: Review

References (14)

1. The ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone in Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT): preliminary results. JAMA 2000;283:1967-1975.
2. Estacio RO, Jeffers BW, Hiatt WR, Biggi SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular events in patients with non-insulin-dependent diabetes and hypertension. . N. Engl. J. Med 1998;338:645-652. (Pubitemid 28108434)
3. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on majorcardiovascular events: results of prospectively-designedoverviews of randomised trials. The Lancet 2003;362:1527-1535.
4. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. . N. Engl. J. Med 2000;342:145-153.
5. Morris J Brown, Christopher R Palmer, Alain Castaigne, Peter W de Leeuw, Giuseppe Mancia, Talma Rosenthal, Luis M Ruilope. Morbidity and mortality in patients randomised to double-blindtreatment with a long-acting calcium-channel blocker or diuretic inthe International Nifedipine GITS study: Intervention as a Goal inHypertension Treatment (INSIGHT). The Lancet 2000;356:366-372. (Pubitemid 30487492)
6. MacMahon S, Neal B. Differences between blood-pressure-lowering drugs. Lancet 2000;356:352-353.
7. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. . J. Natl. Cancer Inst 1959;22:719-748.
8. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahl?f B, Karlberg BE. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study.. The Lancet 2000;356:359-365. (Pubitemid 30487491)
9. Pahor M, Guralnik JM, Corti C, Foley DJ, Carbonin PU, Havlik RJ. Long-term survival and use of antihypertensive medications in older persons.. J. Am. Geriatr. Soc 1995;43:1191-1197.
10. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-625.
11. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739-745.
12. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603. (Pubitemid 28172941)
13. Wright JM, Lee CH, Chambers GK. Systematic review of anti-hypertensive therapies: Does the evidence assist in choosing a first-line drug?. Can Med Assoc J 1999;161:25-32.
14. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, Furberg CD. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000;356(9246):1949-1954 [MEDLINE: 11130522]